ConferenceInt J Radiat Oncol Biol Phys · June 1, 2026
PURPOSE: As survival improves for patients with brain metastases (BM), distinguishing local recurrence (LR) from radionecrosis (RN) is a growing neuro-oncologic challenge. We aimed to develop an explainable deep learning model to noninvasively distinguish ...
Full textLink to itemCite
ConferenceMed Phys · April 2025
BACKGROUND: Stereotactic radiosurgery (SRS) is widely used for managing brain metastases (BMs), but an adverse effect, radionecrosis, complicates post-SRS management. Differentiating radionecrosis from tumor recurrence non-invasively remains a major clinic ...
Full textLink to itemCite
ConferenceNeuro-Oncology · June 12, 2023
AbstractFunctional precision medicine platforms are emerging as promising strategies to improve pre-clinical drug testing and guide clinical decisions. We have developed an organotypic brain slice culture (O ...
Full textCite
ConferenceJournal of Clinical Oncology · June 1, 2023
2013 Background: While brain metastasis (BM) velocity is a valuable prognostic metric at time of intracranial progression (ICP), pre-SRS risk factors for post-SRS high-burden intracranial progression (ICP) remain poorly character ...
Full textCite
ConferenceBreast Cancer Res Treat · January 2023
PURPOSE: Current systemic therapy guidelines for patients with HER2 + breast cancer brain metastases (BCBrM) diverge based on the status of extracranial disease (ECD). An in-depth understanding of the impact of ECD on outcomes in HER2 + BCBrM has never bee ...
Full textLink to itemCite
ConferenceInternational journal of radiation oncology, biology, physics · November 2021
Purpose/objective(s)Improved survival for patients with brain metastases (BM) has been accompanied by a rise in tumor recurrence after stereotactic radiosurgery (SRS). Laser interstitial thermal therapy (LITT) has evolved as an effective treatment ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2021
e14002 Background: It is estimated that 30% of patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will develop brain metastases. Current standard of care options for HER2+ breast canc ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2021
1041 Background: BCBMs are very common in metastatic HER2+ breast cancer. CNS-directed local therapy is the gold standard for treatment, followed by systemic HER2-targeted therapies. In patients with HER2+ BCBM and stable extracr ...
Full textCite
https://orcid.org/0000-0002-8067-2426